AxoGen, Inc. (AXGN) Director Amy Mcbride Wendell Purchases 13,333 Shares of Stock
AxoGen, Inc. (NASDAQ:AXGN) Director Amy Mcbride Wendell acquired 13,333 shares of the company’s stock in a transaction that occurred on Friday, October 7th. The stock was acquired at an average cost of $7.50 per share, for a total transaction of $99,997.50. Following the acquisition, the director now owns 13,333 shares of the company’s stock, valued at approximately $99,997.50. The transaction was disclosed in a filing with the SEC, which can be accessed through this link.
Shares of AxoGen, Inc. (NASDAQ:AXGN) opened at 8.72 on Monday. The company’s market cap is $262.75 million. The firm’s 50-day moving average is $8.74 and its 200-day moving average is $6.99. AxoGen, Inc. has a 1-year low of $4.08 and a 1-year high of $9.88.
AxoGen (NASDAQ:AXGN) last posted its quarterly earnings data on Wednesday, August 3rd. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.12) by $0.03. AxoGen had a negative net margin of 37.90% and a negative return on equity of 193.60%. On average, equities analysts forecast that AxoGen, Inc. will post ($0.40) earnings per share for the current fiscal year.
Institutional investors have recently bought and sold shares of the stock. Nationwide Fund Advisors bought a new position in AxoGen during the second quarter valued at about $105,000. TFS Capital LLC bought a new position in AxoGen during the second quarter valued at about $113,000. Rhumbline Advisers bought a new position in AxoGen during the second quarter valued at about $132,000. Menta Capital LLC bought a new position in AxoGen during the second quarter valued at about $183,000. Finally, KCG Holdings Inc. bought a new position in AxoGen during the second quarter valued at about $200,000. Hedge funds and other institutional investors own 57.87% of the company’s stock.
Separately, Wedbush restated an “outperform” rating and set a $10.00 target price (up previously from $9.00) on shares of AxoGen in a research note on Thursday, August 4th.
Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.